Treatment of SSRI-Resistant Depression: A Meta-Analysis Comparing Within- Versus Across-Class Switches

Biological Psychiatry

Volumn 63, Issue 7, 2008, Pages 699-704

  Papakostas, George I ^a   Fava, Maurizio ^a   Thase, Michael E ^b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Antidepressant; class; depression; remission; resistant; switch

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; DESVENLAFAXINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; PAROXETINE; REBOXETINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DEPRESSION; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZATION; REMISSION; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

BUPROPION; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; HUMANS; MIANSERIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS;

EID: 40149090807     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2007.08.010     Document Type: Article

References (29)

1. Papakostas G.I., and Fava M. Monoamine-based pharmacotherapy. In: Licinio J., and Wong M. (Eds). Biology of Depression: From Novel Insights to Therapeutic Strategies. 1st ed. (2005), Wiley-VCH Verlag, Weinheim, Germany 87-140
2. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry 163 (2006) 28-40
3. Papakostas G.I., Petersen T., Denninger J.W., Tossani E., Pava J.A., Alpert J.E., et al. Psychosocial functioning during the treatment of major depressive disorder with fluoxetine. J Clin Psychopharmacol 24 (2004) 507-511
4. Paykel E.S., Ramana R., Cooper Z., Hayhurst H., Kerr J., and Barocka A. Residual symptoms after partial remission: An important outcome in depression. Psychol Med 25 (1995) 1171-1180
5. Thase M.E. Therapeutic alternatives for difficult-to-treat depression: A narrative review of the state of the evidence. CNS Spectr 9 (2004) 808-816
6. Fava M. Management of nonresponse and intolerance: Switching strategies. J Clin Psychiatry 61 suppl 2 (2000) 10-12
7. Fava M., and Rush A.J. Current status of augmentation and combination treatments for major depressive disorder: A literature review and a proposal for a novel approach to improve practice. Psychother Psychosom 75 (2006) 139-153
8. Petersen T., Dording C., Neault N.B., Kornbluh R., Alpert J.E., Nierenberg A.A., et al. A survey of prescribing practices in the treatment of depression. Prog Neuropsychopharmacol Biol Psychiatry 26 (2002) 177-187
9. Thase M.E., Kremer C., and Rodrigues H. Mirtazapine versus sertraline after SSRI non-response (2001) Presented at the Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU) of the National Institute of Mental Health, May 2001, Phoenix, Arizona
10. Poirier M.F., and Boyer P. Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. Br J Psychiatry 175 (1999) 12-16
11. Rush A.J., Trivedi M.H., Wisniewski S.R., Stewart J.W., Nierenberg A.A., Thase M.E., et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354 (2006) 1231-1242
12. Papakostas G.I., and Fava M. Does the probability of receiving placebo influence the likelihood of responding to placebo or clinical trial outcome?. A meta-regression of double-blind, randomized clinical trials in MDD. Neuropsychopharmacology 31 s1 (2006) s158
13. Fava M., Evins A.E., Dorer D.J., and Schoenfeld D.A. The problem of the placebo response in clinical trials for psychiatric disorders: Culprits, possible remedies, and a novel study design approach. Psychother Psychosom 72 (2003) 115-127
14. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 23 (1960) 56-62
15. Montgomery S.A., and Asberg A. A new depression scale designed to be sensitive to change. Br J Psychiatry 134 (1979) 382-389
16. Trivedi M.H., Rush A.J., Ibrahim H.M., Carmody T.J., Biggs M.M., Suppes T., et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: A psychometric evaluation. Psychol Med 34 (2004) 73-82
17. Baldomero E.B., Ubago J.G., Cercos C.L., Ruiloba J.V., Calvo C.G., and Lopez R.P. Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study. Depress Anxiety 22 (2005) 68-76
18. Lenox-Smith A.J., Schaeffer P., and Willard L. A double-blind study of venlafaxine XR versus citalopram in patients with treatment-resistant depression (2001) Presented at the Annual Meeting of the British Association for Psychopharmacology, July 2001, Harrogate, Yorkshire, England, United Kingdom
19. Papakostas G.I., Thase M.E., Fava M., Nelson J.C., and Shelton R.C. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder?. A meta-analysis of studies of newer agents. Biol Psychiatry (2007) June 21, 2007 [Epub ahead of print]
20. Cipriani A., Barbui C., Brambilla P., Furukawa T.A., Hotopf M., and Geddes J.R. Are all antidepressants really the same?. The case of fluoxetine: A systematic review. J Clin Psychiatry 67 (2006) 850-864
21. Geddes J. Meta-analysis in the assessment of treatment outcome. J Psychopharmacol 20 suppl 4 (2006) 67-71
22. Montgomery S.A., and Andersen H.F. Escitalopram versus venlafaxine XR in the treatment of depression. Int Clin Psychopharmacol 21 (2006) 297-309
23. McGrath P.J., Stewart J.W., Harrison W., and Quitkin F.M. Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor antidepressant. Psychopharmacol Bull 23 (1987) 169-172
24. McGrath P.J., Stewart J.W., Nunes E.V., Ocepek-Welikson K., Rabkin J.G., Quitkin F.M., and Klein D.F. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry 150 (1993) 118-123
25. Ahmed S., Zitek B., Ninan P.T., Pitrosky B., Rosas G., Jiang Q., and Tummala R. Switch from venlafaxine to desvenlafaxine succinate is well tolerated in patients with MDD (2007) Presented at the Annual Meeting of the American Psychiatric Association, May 2007, San Diego, California
26. Fava M., McGrath P.J., Sheu W.P., and Reboxetine Study Group. Switching to reboxetine: An efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine. J Clin Psychopharmacol 23 (2003) 365-369
27. Wohlreich M.M., Mallinckrodt C.H., Watkin J.G., Wilson M.G., Greist J.H., Delgado P.L., and Fava M. Immediate switching of antidepressant therapy: Results from a clinical trial of duloxetine. Ann Clin Psychiatry 17 (2005) 259-268
28. Wohlreich M.M., Martinez J.M., Mallinckrodt C.H., Prakash A., Watkin J.G., and Fava M. An open-label study of duloxetine for the treatment of major depressive disorder: Comparison of switching versus initiating treatment approaches. J Clin Psychopharmacol 25 (2005) 552-560
29. Thase M.E., Rush A.J., Howland R.H., Kornstein S.G., Kocsis J.H., Gelenberg A.J., et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry 59 (2002) 233-239